Last reviewed · How we verify
Gene-Modified Cell Therapy — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Gene-Modified Cell Therapy (Gene-Modified Cell Therapy) — Sorrento Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gene-Modified Cell Therapy TARGET | Gene-Modified Cell Therapy | Sorrento Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gene-Modified Cell Therapy CI watch — RSS
- Gene-Modified Cell Therapy CI watch — Atom
- Gene-Modified Cell Therapy CI watch — JSON
- Gene-Modified Cell Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Gene-Modified Cell Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gene-modified-cell-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing